生物医药公司Eikon Therapeutics(EIKN)今日盘中股价大跌5.61%，引发了市场关注。
消息面上，该公司于今日在纳斯达克首次公开募股(IPO)并挂牌交易。其IPO发行价定为每股18美元，但开盘后股价即低于发行价。这通常反映了市场对新股发行价格的重新评估或投资者对该公司短期表现的谨慎态度。
Eikon Therapeutics由多位诺贝尔化学奖得主联合创立，专注于癌症实验性疗法的研发。其研发进度最快的候选药物EIK1001，正与默沙东的Keytruda联合开展皮肤癌的中后期临床试验，相关中期分析数据预计将于2026年下半年公布。尽管公司拥有知名的创始团队和研发管线，但IPO后的股价表现仍受到市场供需和投资者情绪的影响。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.